A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Monoclonal Gammopathy of Renal Significance

Interventions

DRUG: Cyclophosphamide
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Daratumumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]